摘要
目的分析尿激酶溶栓治疗发病时间不明的急性非重症缺血性卒中患者的风险获益比。方法选取2019年1月~2021年1月期间在龙门县人民医院神经内科接受治疗的发病时间不明的急性非重症缺血性卒中患者118例,将患者按1∶1比例随机分配为溶栓组和对照组,每组59例。两组患者在入院后均进行常规治疗,其中对照组采用生理盐水治疗,溶栓组则采用尿激酶静脉溶栓治疗。分析两组患者的临床疗效,并比较两组患者的美国国立卫生研究院卒中量表(NIHSS)治疗前后评分和改良Rankin评分量表(m RS)治疗前后评分情况,通过对患者治疗后进行90 d的访视工作,观察两组患者的致残率和脑出血发生率。结果治疗后,溶栓组的临床有效率为98.31%,显著高于对照组的81.36%(P<0.05);治疗前两组患者NIHSS评分差异无统计学意义。溶栓组评分(6.26±1.37)分,较治疗前显著下降,且显著低于对照组治疗后评分(P<0.05);治疗前两组患者m RS评分差异无统计学意义,治疗后溶栓组评分显著下降且显著低于对照组(P<0.05)。结论尿激酶溶栓治疗发病时间不明的急性非重症缺血性卒中患者临床疗效确切,对患者的神经功能和预后效果具有显著的改善作用,同时价格低廉。
Objective To analyze the risk benefit ratio of urokinase thrombolysis in patients with acute non severe ischemic stroke whose onset time is unknown.Methods 118 patients with acute non severe ischemic stroke with unknown onset time who were treated in the Department of Neurology of Longmen County People’s Hospital from January 2019 to January 2021 were randomly divided into thrombolytic group and control group according to the ratio of 1:1,with 59 cases in each group.The patients in both groups received routine treatment after admission.The control group was treated with normal saline,and the thrombolytic group was treated with urokinase intravenous thrombolysis.The clinical efficacy of the two groups of patients was analyzed,and the scores of the National Institutes of Health Stroke Scale(NIHSS)and the modified Rankin scale(mRS)before and after treatment were compared between the two groups.The disability rate and cerebral hemorrhage rate of the two groups of patients were observed through a 90-day visit after treatment.Results After treatment,the clinical effective rate of thrombolysis group was 98.31%,significantly higher than 81.36%of the control group(P<0.05);There was no significant difference in NIHSS score between the two groups before treatment.After treatment,the score of thrombolysis group(6.26±1.37)was significantly lower than that of the control group(P<0.05);There was no significant difference in mRS scores between the two groups before treatment,and the score of thrombolysis group decreased significantly and was significantly lower than that of the control group after treatment(P<0.05).Conclusion Urokinase thrombolysis is effective in the treatment of acute non severe ischemic stroke patients whose onset time is unknown.It can significantly improve the neurological function and prognosis of patients.At the same time,its price is low.
作者
朱建忠
王珊
ZHU Jian-zhong;WANG Shan(Department of Neurology,Longmen County People's Hospital,Huizhou 516800,China)
出处
《中国处方药》
2023年第1期88-90,共3页
Journal of China Prescription Drug
基金
2020惠州市科技计划(医疗卫生)项目(2020Y380)。
关键词
尿激酶
溶栓治疗
急性非重症缺血性卒中
风险获益
Urokinase
Thrombolytic therapy
Acute non severe ischemic stroke
Risk benefit
